Secukinumab Biosimilar, Human IL17A Monoclonal Antibody

Additional Information:
| Secukinumab Biosimilar, Human IL17A Monoclonal Antibody Recombinant fully human IgG1 monoclonal antibody. Isotype: Human IgG1 kap|The monoclonal antibody secukinumab biosimilar was produced in the mammal cells. Specificity/Sensitivity: The monoclonal antibody secukinumab biosimilar specifically binds to the human IL17A. Applications: ELISA, neutralization, functional assays such as bioanalytical PK and ADA assays, and those assays for studying biological |0.2 uM filtered solution, pH 5.8, no stabilizers or preservatives. Endotoxin: Purity: >95% by SDS-|The research grade secukinumab biosimilar protein is shipped with ice |Use a manual defrost freezer and avoid repeated freeze-thaw cycles. 12 months from date of receipt, -20 to -70°C as supplied. 1 month from date of receipt, 2 to 8°C as supplied. |Background What is secukinumab biosimilar research grade? Research grade secukinumab biosimilar uses the same protein sequences as the therapeutic antibody secukinumab. Secukinumab, the humanized anti-IL17A monoclonal antibody, inhibits interleukin 17A, which is a member of the cytokine family, and produced mainly by inflammatory T helper 17 cells. IL17A is upregulated in serum of people with psor and in the synov fluid of people with psor arthritis, and promotes inflammation when it binds to the interleukin-17 receptor which is expressed in various types of cells, including keratinocytes in skin. Syd Labs also provides the following cytokine antibody biosimilar: Br Biosimilar, research grade, anti-human IL-12/IL-23 monoclonal antibody |Bevacizumab Biosimilar, research grade (VEGF-A) Ranibizumab Biosimilar, research grade (VEGF-A, Fab produced in E. coli) Cetuximab Biosimilar, research grade (HER1, ErbB-1, EGFR) Panitumumab Biosimilar, research grade (HER1, ErbB-1, EGFR) Trastuzumab Biosimilar, research grade (HER2, ErbB-2, c-neu) Pertuzumab Biosimilar, research grade (HER2, ErbB-2, c-neu) Infliximab biosimilar, research grade (TNF alpha) Adalimumab biosimilar, research grade (TNF alpha) Rituximab biosimilar, research grade (CD20) Denosumab biosimilar, research grade (RANKL, RANK ligand, OPGL, TNFSF11, CD254, TRANCE, ODF) Palivizumab Biosimilar, research grade (RSV) Omalizumab biosimilar, research grade (IgE) Eculizumab biosimilar, research grade (C5)